Gene Therapy: US FDA Labeling For Vertex’s Casgevy, Bluebird’s Lyfgenia Reflect Different Risks

 
• By Sue Sutter
Apples and oranges
The first gene therapies for sickle cell disease have some substantial differences in safety labeling. • Source: Shutterstock

More from Approvals

More from Product Reviews